Inappropriate activation of Abl family kinases plays a crucial role in dierent human leukaemias. In addition to the well known oncoproteins p190Bcr-Abl and p210Bcr-Abl, Tel-Abl, a novel fusion protein resulting from a dierent chromosomal translocation, has recently been described. In this study, the kinase speci®cities of the Bcr-Abl and Tel-Abl proteins were compared to the physiological Abl family kinases c-Abl and Arg (abl related gene). Using short peptides which correspond to the target epitopes in known substrate proteins of Abl family kinases, we found a higher catalytic promiscuity of Bcr-Abl and Tel-Abl. Similar to Bcr-Abl, Tel-Abl was found in complexes with the adapter protein CRKL. In addition, c-Crk II and CRKL are tyrosine phosphorylated and complexed with numerous other tyrosine phosphorylated proteins in Tel-Abl expressing Ba/F3 cells. GTPase analysis with a Ras´GTP-speci®c precipitation assay showed constitutive elevation of GTPloaded Ras in cells expressing the leukaemic Abl proteins. The mitogenic MAPK/Erk kinases as well as Akt/PKB, a kinase implicated to negatively regulate apoptosis, were also constitutively activated by both BcrAbl and Tel-Abl. The results indicate that the leukaemic Abl-fusion proteins have catalytic speci®cities dierent from the normal kinases c-Abl and Arg and that Tel-Abl is capable to activate at least some pathways which are also upregulated by Bcr-Abl.
Introduction
The family of human Abl tyrosine kinases consists of the normal cellular proteins c-Abl and Arg and dierent pathological forms (Kolibaba and Druker, 1997; Raitano et al., 1997; Sawyers, 1999) . They are the most complex of all known non-receptor tyrosine kinases. The amino-terminal part of c-Abl is similar to that of many Src family kinases, in which Src homology domains (SH3 and SH2) precede the catalytic domain. A 90 kDa C-terminal domain includes potential actin-and DNA-binding domains, a nuclear localization signal, and binding sites for the adapter proteins Crk/CRKL, Grb2 and Nck Ren et al., 1994) . c-Abl and the Arg kinase (product of the abl related gene) share 90 ± 95% identity in the SH2, SH3 and catalytic domains, whereas their C-terminal parts are much more diverse, with only approximately 30% overall identity (Kruh et al., 1986 (Kruh et al., , 1990 .
Most chronic myelogenous leukaemias (CML) and some acute lymphocytic leukaemias result from a reciprocal translocation, t(9;22)(q34;q11), cytogenetically detectable by the presence of the Philadelphia chromosome. At the molecular level, the c-abl gene located on chromosome 9 is fused to the bcr gene (breakpoint cluster region), which is located on chromosome 22 (Heisterkamp et al., 1985) . Depending on the breakpoint in the bcr gene dierent chimeric proteins result, most commonly the Bcr-Abl fusion proteins p190 and p210. The Bcr part in the fusion protein forms an a-helical`coiled-coil' structure, which leads to the oligomerization of Bcr-Abl molecules, autophosphorylation and activation of the catalytic activity (McWhirter et al., 1993) . Among the signalling pathways which are activated by Bcr-Abl are the Ras-MAPK/Erk (Pendergast et al., 1993; Puil et al., 1994; Tauchi et al., 1998) , the PI3 kinase-Akt/PKB (Skorski et al., 1997) and the JNK-c-Jun pathway (Raitano et al., 1995) . Moreover, p210Bcr-Abl and p190Bcr-Abl have been shown to induce transformation of haematopoietic cells (McLaughlin et al., 1989) and to produce leukaemias in mice (Daley et al., 1990; Elefanty et al., 1990; Heisterkamp et al., 1990) .
In some human leukaemias a dierent Abl fusion protein has been found, which involves Tel, a gene located on chromosome 12 (Papadopoulos et al., 1995; . Tel (Translocation, ets, leukaemia, also known as ETV6) is a transcription factor of the Ets family and its amino-terminal sequence encodes a helix ± loop ± helix motif, which may mediate dimerization and subsequent Abl kinase domain activation (Hannemann et al., 1998) , somewhat reminiscent of the situation in Bcr-Abl kinases.
The cytoplasmic adapter proteins c-Crk II and CRKL (ten Hoeve et al., 1994; de Jong et al., 1997) were the ®rst good substrate proteins identi®ed for c-Abl (reviewed in Feller et al., 1998) .
Other known Abl substrates are p130Cas, an SH3-domain containing multidocking protein that can localize to focal adhesions , and the C-terminal domain of RNA polymerase II (Baskaran et al., 1993) . CRKL and p130Cas are proteins prominently phosphorylated in Bcr-Abl expressing cells (Nichols et al., 1994; Oda et al., 1994; ten Hoeve et al., 1994; Salgia et al., 1996) .
The substrate sequence preferred by the Abl kinase in a peptide library screen is similar, but not identical, to motifs contained in the cellular c-Abl and Bcr-Abl substrate proteins c-Crk II, CRKL and p130Cas (Songyang et al., 1995) . The relevance of a proline in position +3 after the target tyrosine, which is also contained in c-Crk II, CRKL and p130Cas, could thus be con®rmed experimentally. In contrast, the oncogenic kinase v-Src prefered substrate peptides rich in negatively charged residues, according to the same authors.
Since all Abl family members contain several protein-protein interaction domains, it is not possible to clearly de®ne alterations in the speci®city of the catalytic domain between normal and leukaemic Abl forms by using substrate proteins. Therefore, we have addressed this question with in vitro phosphorylation of synthetic peptides derived from known target epitopes with dierent Abl kinases. The results demonstrate that the leukaemic Abl proteins Bcr-Abl and Tel-Abl have an altered preference for synthetic substrate peptides. Furthermore, we have found TelAbl to mediate tyrosine-phosphorylation of Crk/ CRKL, the formation of Crk/CRKL-dependent protein ± protein complexes and constitutive activation of Ras, MAPK/Erk and Akt/PKB.
Results and discussion

Altered catalytic specificity of human leukaemic Abl kinases
It has been a long standing question whether leukaemic Abl proteins display an altered substrate speci®city or merely an constitutively elevated tyrosine kinase activity. With the identi®cation of`in vivo' and`in vitro' substrates eciently phosphorylated by Abl kinases namely c-Crk II, CRKL and p130Cas Mayer et al., 1995; de Jong et al., 1997) , it has become possible to use short peptides which correspond to the phosphorylation sites in these proteins as substrates. These peptides are unlikely to interact with regions outside the catalytic cleft. We used these peptides in immunocomplex kinase assays as substrates for Abl family kinases precipitated from dierent cell lines.
The synthetic substrate peptides (SP1 to SP12) are listed in Table 1 . SP1 is the substrate peptide derived from the peptide library screen (Songyang et al., 1995) . It was by far the best substrate peptide of the panel for the normal cellular c-Abl and Arg proteins (Figure 1 ). SP2 and SP3 correspond to the c-Crk II region around tyrosine 221, which is phosphorylated by c-Abl . The longer peptide SP2 was in all cases a slightly better substrate than SP3. In SP4 the serine residue of the SP3 sequence is replaced by alanine to remove the hydroxyl group, which may serve as a phosphate acceptor site, but no signi®cant loss in phosphorylation was observed in this control.
SP5 and SP6 are peptides derived from the Abl target sites in CRKL (de Jong et al., 1997) and p130Cas , respectively. Although both contain a proline following the tyrosine in position +3, less phosphate incorporation was observed for SP5, whereas SP6 reaches similar levels as the Crk-derived peptides. SP7 corresponds to the consensus motif of the repetitive sequence found in the C-terminal domains (CTDs) of all eukaryotic RNA polymerase II proteins (Baskaran et al., 1993) and turned out to be the poorest of all substrate peptides tested. Mutation of the proline in SP1 to an alanine or histidine (SP8 and SP9) signi®cantly reduced the phosphorylation of these peptides by c-Abl and Arg. However, this reduction was only slight for the leukaemic Abl proteins Bcr-Abl and Tel-Abl, documenting a ®rst dierence in peptide substrate preferences between normal and oncogenic forms of Abl family kinases.
The peptide sequences of SP10 and SP11 are derived from the peptide substrate library screen with v-Src (Songyang et al., 1995) . When compared to the best substrate peptide for all Abl kinases (SP1), SP10 and SP11 are much more eciently phosphorylated by Bcr- Table 1 Peptides synthesized for analysis of Abl kinases speci®city
SP1
Abl substr. libr. cons. wt
The substrate library consensus motif found in the peptide library screen with Abl or v-Src (Songyang et al., 1995) is included in substrate peptide 1 (SP1) and SP8 ± SP11 as wildtype (wt) or dierent mutations (mut.) of position +3 after the tyrosine to alanine, histadine, or proline. SP2 ± SP5 correspond to the indicated amino acids of substrate proteins of Abl kinases. SP6 and SP7 represent the consensus motif of the phosphate acceptor sites found in p130Cas and in the C-terminal domains (CTD) of the RNA polymerase II, respectively. SP12 represents the autophosphorylation site around tyrosine 177 (amino acids 173 ± 182) in the Bcr part of Bcr-Abl. Single letter code is used for amino acid abbreviation. Three lysine residues were added to all peptides for technical reasons
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Abl and Tel-Abl than by c-Abl and Arg. Interestingly, replacement of the phenylalanine in position +3 of SP10 by proline (SP11) did not lead to an increase in phosphorylation by Abl kinases. Finally, the Bcr-Abl epitope around the autophosphorylated tyrosine 177 in Bcr (SP12) was found to be a relatively poor substrate. Taken together, our data give initial hints that the oncogenic forms of the Abl family kinases are able to eciently phosphorylate a much wider range of substrates than the cellular forms. Of course, the situation in intact cells is strongly in¯uenced by other factors, including the subcellular compartmentalization and interactions between domains other than the kinase domain and the substrate epitope. Using peptides containing only the substrate epitope itself, exclusively the speci®city of the catalytic domains was determined, without the in¯uence of other proteinprotein interactions. These in vitro data must still be con®rmed in vivo. The development of in vivo kinase assays using small peptide substrates is thus an important goal for future studies.
Complexes between Crk adapters, Tel-Abl and tyrosine-phosphorylated proteins
Since even p190Bcr-Abl and p210Bcr-Abl have been reported to dier in their eect on certain signalling pathways (Ilaria and Van Etten, 1996) , it is not obvious which pathways will be eected by Tel-Abl. This was analysed in subsequent experiments. CRKL forms stable complexes with Bcr-Abl and references therein) . In co-immunoprecipitation studies we detected similar complexes between CRKL and Tel-Abl in Ba/F3 cells (Figure 2a ). This interaction made it likely that CRKL and possibly cCrk II are phosphorylated by the activated Tel-Abl kinase. Indeed, c-Crk II and CRKL were tyrosine phosphorylated in Ba/F3 cells expressing Tel-Abl (Figure 2b) . Furthermore, both c-Crk II and CRKL were signi®cantly retarded in their migration in SDS ± PAGE when Tel-Abl was expressed (Figure 2b) , which is usually indicative of a hyperphosphorylated state. Considering that Crk-derived peptides are similarly phosphorylated by Bcr-Abl and Tel-Abl (Figure 1) , the results strongly suggest that Tel-Abl can directly phosphorylate Crk adapter proteins. Further analysis of Crk and CRKL precipitates from Tel-Abl expressing Ba/F3 cells revealed that a considerable number of tyrosine-phosphorylated proteins is coprecipitated (Figure 2c) . These proteins have apparent molecular masses of 50 ± 150 kDa and were not detectable in precipitates from the parental cell line. The SH2 domains of Crk and CRKL are selective for certain tyrosine phosphorylated sequences (Songyang et al., 1993) . According to our results ( Figure 1 ) these sequences are also recognised as substrate motifs by the Tel-Abl kinase. Thus, it seems likely that the presence of Tel-Abl leads to a constitutive activation of Crk/CRKL-dependent signalling pathways.
Constitutive activation of the Ras/Erk and Akt/PKB signalling pathways by oncogenic Abl forms
The Grb2 docking site containing tyrosine 177, which is present in the Bcr part of Bcr-Abl (Pendergast et al., 1993) , is absent in Tel-Abl. However, Crk and CRKL can bind to GTPase regulators like SoS and C3G Feller et al., 1995) and may thus aect the activity of GTPases like Ras and Rap1. Using a recently developed precipitation assay for GTP-loaded Ras (Taylor and Shalloway, 1996; Posern et al., 1998) , it was investigated whether the expression of Tel-Abl leads to a constitutive elevation of Ras´GTP in the absence of serum in the culture medium. p190Bcr-Abl and p210Bcr-Abl expressing Ba/F3 cells, as well as parental Ba/F3 cells, were also analysed. Expression of leukaemic Abl proteins led in all cases to a permanent elevation of Ras´GTP (Figure 3a) . Ras Figure 1 Comparison of the substrate speci®city of Abl family kinases using a panel of synthetic substrate peptides. Substrate peptides SP1 ± SP12 (see Table 1 ) were subjected to phosphorylation by the nonleukaemic Abl kinases c-Abl and Arg (precipitated from NIH3T3 cells with anti-Abl (Ab-3) and from Abl activation by Bcr-Abl expression in haematopoietic cells has already been reported by others (Pendergast et al., 1993; Puil et al., 1994; Tauchi et al., 1998) . The starved parental Ba/F3 cells were still able to respond to stimulation with Interleukin-3 containing WEHI-3-conditioned medium (WCM) with Ras activation, as was previously reported. Ras is well known to aect the mitogenic Raf ± MEK ± MAPK/Erk cascade in many dierent cell types. Consistent with this, MAPK/Erk was constitutively activated by Tel-Abl and the Bcr-Abl proteins as indicated by activationspeci®c antibodies (Figure 3b) .
Another signalling protein which is aected in its activity by the expression of Bcr-Abl and can form complexes with CRKL and Crk, possibly via the c-Cbl protein, is the Pl3 kinase Skorski et al., 1997) . Akt/PKB is a downstream eector of Pl3 kinase in Bcr-Abl expressing cells (Skorski et al., 1997) . Using an activation-speci®c antiserum which recognizes exclusively the Ser473-phosphorylated kinase-active form of Akt/PKB, it was found that Akt/PKB is constitutively activated under condition of serum deprivation when Tel-Abl or Bcr-Abl kinases are expressed (Figure 4) . Together, the results document that major mitogenic and cell survival pathways are similarly aected by human leukaemia-causing Abl oncogenes.
The aim of this investigation was to de®ne similarities and dierences between the known forms of human leukaemic Abl proteins and to compare their catalytic and signalling properties to the normal cellular Abl family kinases. Results of earlier studies using tyrphostins, which preferentially inhibit certain Abl family kinases, and large synthetic tyrosine- containing polypeptide-copolymers, suggested that dierences in kinase speci®city may exist (Ana® et al., 1992) . In order to address such alterations of the catalytic speci®city of Abl kinase domains we have chosen an`in vitro' approach using synthetic peptides derived from known substrate proteins, and found a higher promiscuity of Bcr-Abl and Tel-Abl, distinct from c-Abl and Arg. If dierences in the catalytic properties of oncogenic Abl kinases compared with their normal cellular counterparts can be characterized in detail, it should be possible to design small inhibitory compounds with selectivity for leukaemiacausing Abl kinases. However, further studies will be necessary to ®nd additional hints on how such inhibitors should be constructed.
With respect to prominent signalling pathways which regulate cell survival and proliferation, namely Ras ± MAPK/Erk and PI3 kinase ± Akt/PKB, the initial data presented here indicate that there are signi®cant similarities in the signalling events initiated by BcrAbl and Tel-Abl proteins. Similarly, the association of CRKL with Tel-Abl, the tyrosine-phosphorylation of c-Crk and CRKL and their complex formation with numerous, presumably SH2 domain binding proteins are highly reminiscent of the situation in Bcr-Abl transformed cells (Nichols et al., 1994; Oda et al., 1994; ten Hoeve et al., 1994; Salgia et al., 1996; Sattler et al., 1996) . This is not unexpected, given the structural similarity of Bcr-Abl and Tel-Abl and the similar patterns of phosphotyrosyl-containing proteins detected by a previous study . These authors did not provide a detailed analysis of the catalytic properties of Tel-Abl and the functional consequences of its expression in haematopoietic cells remained largely unclear. Since the chromosomal translocation underlying the generation of the Tel-Abl protein appears to be a rare event (Nilsson et al., 1998) , it will be probably not be possible for some time to study a considerable number of patient-derived samples. However, widely used model systems like the murine Ba/F3 cells and similar cell lines allow at least some insight into the events triggered by the expression of the leukaemic Tel-Abl kinase.
Materials and methods
Peptide synthesis
Synthesis was carried out by the Fmoc (¯uorenylmethoxy-carbonyl)/t-butyl based solid phase peptide chemistry method on a SMPS 350 (Zinsser Analytic) synthesizer. The peptides were deprotected and cleaved from the resin with tri¯uoro-acetic acid/ethanedithiol/water, 94 : 3 : 3, for 120 min. After ®ltration, precipitation with cold ter-butyl methyl ether and lyophilisation, the crude peptides were puri®ed by reversephase HPLC on a preparative Vydac C18 column (250625 mm) with linear gradients of 80% acetonitrile plus 0.05% tri¯uoroacetic acid versus 0.07% aqueous tri¯uoro-acetic acid. Correct mass was con®rmed by electrospray mass spectrometry (Sciex API III, Perkin Elmer). Pure fractions were pooled, and the ®nal product was analysed by reversephase HPLC on a Vydac C18 column (25064.6 mm) and capillary zone electrophoresis (Biofocus 3000, BioRad). The three lysines at the C-terminus of all substrate peptides were added to reduce the peptide mobility in SDS-gels and to allow peptide binding to negatively charged membranes.
Antibodies and cell lines
Anti-Abl (mAb 8E9) was a gift of J Wang (UC San Diego, USA), anti-Arg (polyclonal rabbit) a gift of T Shishido and H Hanafusa (Osaka Bioscience Institute (OBI), Osaka, Japan). Anti-Tel (polyclonal rabbit, anti-NH2-Tel) has been previously described (Poirel et al., 1997) . The following antibodies were from commercial sources: anti-Myc (Clone 9E10, NeoMarkers, Fremont, CA, USA), anti-Bcr (mAb Ab-2, Oncogene Science/Calbiochem), anti-Abl (mAb Ab-3; Oncogene Science/Calbiochem), anti-Phospho p44/42 MAP Kinase (Thr202/Tyr204) (New England BioLabs), anti-MAPK/Erk 1 (C-16, Santa Cruz Biotechnology) antiPhospho-Akt/PKB (Ser473) and anti-Akt/PKB (New England Biolabs), anti-CRKL (C-20, Santa Cruz Biotechnology), anti-Crk (Transduction Laboratories), anti-Ras (Transduction Laboratories), anti-phosphotyrosine (PY20, Transduction Laboratories). Immunoprecipitation was performed using protein G-Sepharose (Pharmacia) for monoclonal antibodies or protein A-Sepharose (Pharmacia) for polyclonal antibodies. Western blots were developed with the ECL detection system (Amersham). WEHI-3-conditioned medium (WCM) was used as a source of Interleukin-3 (IL-3). Ba/F3 parental cells and Ba/F3 cells expressing Myc-tagged Tel-Abl (Hannemann et al., 1998) or p190 and p210Bcr-Abl (Ahmed et al., 1998) (Baskaran et al., 1997) were grown in DMEM containing 10% FBS.
Kinase assays
RIPA-lysates were prepared as described (Oehrl et al., 1998) . The antibodies used for immuno-complex kinase assay were selected for best speci®city: c-Abl was precipitated from NIH3T3 cell lysates with anti-Abl (Ab-3), Arg with polyclonal anti-Arg serum from Abl 7/7 /cell lysates, Bcr-Abl with anti-Bcr from NIH3T3 Bcr-Abl cell lysates and Tel-Abl from Ba/F3 Tel-Abl cell lysates with anti-Myc. The amounts of cellular lysate used for the immunoprecipitations were adjusted so that the total incorporation of phosphate was in a similar range for all kinases (data not shown). After incubation with the immobilized antibodies overnight, washing twice with RIPA buer and once with kinase buer without ATP, the substrate peptides were added to a ®nal concentration of 120 mM. The kinase reaction was done in a volume of 50 ml for 1 h at 208C in kinase buer containing 500 nM unlabelled ATP and 1 mCi 32 P-g-ATP (3000 Ci/mmol). The samples were subjected to 20% SDS ± PAGE (separating gel with 375 mM TrisHCl pH 9.3, 10% glycerol) and quanti®ed by phosphoimager (Fujix BAS-2000 III, Fuji). Figure 4 Constitutive Akt/PKB activation in Ba/F3 cells expressing leukaemic Abl proteins. Cells were treated and lysed as described in Figure 3b and analysed for the presence of phospho-Akt/PKB or total Akt/PKB by Western blotting. Lysates of NIH3T3 stimulated with PDGF were provided by the commercial source as a positive control
Co-immunoprecipitations
For analysis of CRKL/Tel-Abl complexes, Ba/F3 Tel-Abl cells and parental Ba/F3 cells were extracted with 1% Triton X-100 lysis buer as described previously (Oehrl et al., 1998) . After preclearing on protein A-Sepharose and preabsorption on immobilized immunoglobulins from normal rabbit serum, the supernatant was ®nally incubated overnight with immobilized anti-CRKL or an equal amount of immunoglobulins from non-immunized rabbits as indicated. The precipitates were washed three times with lysis buer supplemented with 0.5% deoxycholate. Precipitated proteins were separated by 7% SDS ± PAGE and blotted with anti-Tel antibody.
For analysis of c-Crk/CRKL phosphorylation, 1 mg of RIPA-lysates were immunoprecipitated for 3 h with 2 mg of anti-Crk or anti-CRKL antibodies. As controls, unspeci®c antibodies of the same isotype were used. Precipitates were washed three times with Triton X-100 lysis buer and separated by 10% SDS ± PAGE. Blots were probed with anti-phosphotyrosine antibody (PY20) and subsequently reprobed with anti-Crk or anti-CRKL antibodies.
Analysis of Ras, MAPK/Erk and Akt/PKB activity
Analysis of GTP-loaded Ras was performed as described earlier (Taylor and Shalloway, 1996; Posern et al., 1998) : Ba/ F3 cells were washed twice in RPMl1640 without serum, starved for 24 h in the same medium and stimulated for 10 min with WCM as indicated. Cells were lysed in Mg 2+ -containing lysis buer (MLB) and further analysed as described (Taylor and Shalloway, 1996; Posern et al., 1998) .
For analysis of MAPK/Erk and Akt/PKB activity, cells from a growing culture were washed once with PBS and once with serum-free RPMl1640. They were then resuspended in medium with 0.5% calf serum and maintained for 18 h. As indicated, cells were stimulated for 10 min with WCM prior to harvest. Cells were lysed in RIPA buer containing phosphatase inhibitors (10 mM sodium pyrophosphate, 10 mM NaF, 20 mM b-glycerophosphate, 1 mM sodiumortho-vanadate, 1 mM sodium molybdate). Two hundred mg of total cell lysate were separated by 11% SDS ± PAGE, blotted and probed with anti-phospho-MAPK/Erk, anti-MAPK/Erk, anti-phospho-Akt/PKB, or anti-Akt/PKB antibodies.
